Maeda Takahiro, Kikuchi Eiji, Hasegawa Masanori, Homma Keiko, Ando Toshiyuki, Suzuki Kenjiro, Kaneko Gou, Mizuno Ryuichi, Miyajima Akira, Oya Mototsugu
Department of Urology, Keio University School of Medicine, Tokyo, Japan.
Department of Laboratory Medicine, Keio University School of Medicine, Tokyo, Japan.
Int J Urol. 2018 Jan;25(1):70-74. doi: 10.1111/iju.13470. Epub 2017 Oct 3.
To clarify the effects of dutasteride on serum hormone levels and aging male symptoms in patients with benign prostatic enlargement.
The present prospective study was carried out in 110 symptomatic benign prostatic enlargement patients treated with daily administration of 0.5 mg dutasteride. We analyzed serum hormonal levels and aging related symptoms using a validated Aging Male Symptom questionnaire at baseline and after 3 months of dutasteride treatment.
The mean total testosterone, free testosterone and luteinizing hormone levels after dutasteride treatment were approximately 20% higher than those at baseline. The percentage increases in total and free testosterone levels were negatively correlated with these baseline levels. Baseline age, levels of total testosterone and free testosterone, and the changes in the rate of luteinizing hormone after dutasteride treatment tended to be correlated with an increase in the rate of total testosterone and free testosterone after dutasteride treatment. In a subgroup of 26 patients with moderate-to-severe aging male symptoms, poor morning erection and free testosterone levels <8.5 pg/mL, total aging male symptoms, and somatic symptoms scores significantly decreased after dutasteride treatment with an increase of total and free testosterone.
The increase of endogenous free testosterone and total testosterone by dutasteride might bring additional benefits of improvement of aging male-related symptoms, especially in patients with lower free testosterone baseline levels and moderate-to-poor aging-related symptoms.
阐明度他雄胺对良性前列腺增生患者血清激素水平及男性衰老症状的影响。
本前瞻性研究纳入了110例有症状的良性前列腺增生患者，每日给予0.5mg度他雄胺治疗。在基线时以及度他雄胺治疗3个月后，我们使用经过验证的男性衰老症状问卷分析血清激素水平和与衰老相关的症状。
度他雄胺治疗后，平均总睾酮、游离睾酮和促黄体生成素水平比基线时约高20%。总睾酮和游离睾酮水平的升高百分比与这些基线水平呈负相关。基线年龄、总睾酮和游离睾酮水平，以及度他雄胺治疗后促黄体生成素水平的变化往往与度他雄胺治疗后总睾酮和游离睾酮水平的升高相关。在26例有中度至重度男性衰老症状、晨勃不佳且游离睾酮水平<8.5pg/mL的患者亚组中，度他雄胺治疗后，随着总睾酮和游离睾酮水平升高，男性衰老症状总分及躯体症状评分显著降低。
度他雄胺使内源性游离睾酮和总睾酮增加，可能会给改善男性衰老相关症状带来额外益处，尤其是对于游离睾酮基线水平较低且有中度至重度衰老相关症状的患者。
